Six-month follow-up data on Kymriah (tisagenlecleucel) will bring relief at Swiss pharma giant Novartis (NOVN: VX) and at other drugmakers developing CAR-T therapies.
In August, Kymriah became the first CAR-T-cell-directed therapy to be approved by the US Food and Drug Administration (FDA). Its speedy approval came on the back of only mid-stage data and the FDA approved a Risk Evaluation and Mitigation Strategy (REMS) for the treatment, as part of which Novartis has been establishing a network of certified treatment centers throughout the USA.
"We have been able to significantly increase their chance of achieving and maintaining a sustained response without stem cell transplant"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze